Article

OBJECTIVE: To investigate whether the incidence of neutropenia was higher in
subjects who received a combination treatment with valproate and quetiapine than
in those who were administered monotherapy. DESIGN: Retrospective cohort study.
SETTING: Rehabilitation department of a university hospital. PARTICIPANTS:
Patients with acquired brain injuries who had taken valproate for seizures or
quetiapine for delirium for >7 days (N=101). Data were extracted from electronic
medical records of the hospital. INTERVENTIONS: Not applicable. MAIN OUTCOME
MEASURES: Incidence of neutropenia (absolute neutrophil count<2000 cells/muL) was
elicited from the weekly complete blood cell records for 71.07+/-43.71 days of
observation. The odds ratio for neutropenia development was calculated and
adjusted for variables that showed significant differences between patients with
or without neutropenia. RESULTS: The incidence of neutropenia was significantly
higher in the group receiving the combination treatment than in those receiving
the monotherapy (32.26% vs 12.90%, adjusted P=.036), despite a lack of any
differences in the daily doses of the medications. Coadministration of quetiapine
and valproate was the predictor of neutropenia development when age, body weight,
and underlying diseases were adjusted in the logistic regression model (odds
ratio=3.749; 95% confidence interval, 1.161-12.099; P=.027). CONCLUSIONS:
Administration of quetiapine together with valproate in patients with acquired
brain injury could increase the incidence of medication-induced neutropenia.
CI - Copyright (c) 2016 American Congress of Rehabilitation Medicine. Published by
Elsevier Inc. All rights reserved.

Langue : ANGLAIS